US20030224059A1 - Drug microparticles - Google Patents

Drug microparticles Download PDF

Info

Publication number
US20030224059A1
US20030224059A1 US10400100 US40010003A US2003224059A1 US 20030224059 A1 US20030224059 A1 US 20030224059A1 US 10400100 US10400100 US 10400100 US 40010003 A US40010003 A US 40010003A US 2003224059 A1 US2003224059 A1 US 2003224059A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
drug
solid solution
carrier
particles
sublimable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10400100
Inventor
E. Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/06Making microcapsules or microballoons by phase separation
    • B01J13/12Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent

Abstract

Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.

Description

    RELATED APPLICATIONS
  • The present Application claims the benefit of the Mar. 26, 2002 filing date of U.S. Provisional Patent Application No. 60/367,957.[0001]
  • FIELD OF THE INVENTION
  • The present invention relates to microparticles of drugs, especially drugs that are poorly soluble in water, and to methods for making them. [0002]
  • BACKGROUND OF THE INVENTION
  • Many important drugs have poor oral bioavailability because they are poorly soluble in water. Many approaches have been suggested to overcome this problem. Although some approaches have been used, with limited commercial success, each approach has its own drawbacks and limitations. [0003]
  • In one approach, a water-soluble prodrug of a poorly water-soluble drug is made [1-4]. The prodrug approach is limited to those molecules that have functionality amenable to facile removal in the body to form the drug. Not all poorly water-soluble drugs are so endowed. Furthermore, the prodrug would likely be considered a new chemical entity and require separate approval from regulatory agencies, adding considerable time and cost to bringing the product to market. [0004]
  • The bioavailability of poorly water-soluble drugs has been improved by decreasing the particle size of the drug to increase the surface area. Milling [5-6], high pressure homogenization [7-8], spray drying [9], lyophilization of solutions in water—organic solvent mixtures [10], and lyophilization of solutions inorganic solvents [11-12] have been tried. Size reduction is, in principal, generally applicable for improving bioavailability, but achieving size reduction by, for example, high energy milling, requires special equipment and is not always applicable. High pressure homogenization requires special equipment and requires organic solvents that can remain in the comminuted product. Spray drying also requires solvents and generally produces particles that are too large. [0005]
  • Lyophilization is usually limited to materials that are soluble in water in any event, although there have been some efforts at using organic solvents. [0006]
  • The solubility of poorly soluble antibiotics has been improved by complexation with polymers or cyclodextrins. Polymer complexes have been formed with PVP in organic solvent [13a], or with PVP in heated water [13]. Other drugs have been complexed with cyclodextrins and polymers [14-15]. [0007]
  • The bioavailability of poorly soluble drugs has been improved by dispersing the drug in a soluble polymer, often with addition of surfactants [16-24]. [0008]
  • Some combinations of techniques have shown added improvement. For example spraying and drying a dispersion of drug and polymer or cyclodextrin on pellets in a fluidized bed dried [25-26]. The combination of solid dispersion and lyophilization to improve solubility has been demonstrated [27], and the use of solid dispersions absorbed on a carrier having a large surface area has also been demonstrated [28]. [0009]
  • Clearly, there is a need for a simpler and generally applicable means of making and delivering particles of drugs having a size below 10 μm and especially below 1 μm. [0010]
  • Many of the above-described techniques require forming particles by solvent removal which, in turn, entails concentration of a solution. During solution concentration, solute molecules, which in solution are statistically separated into individual molecules and small clusters or aggregates, are drawn together to form larger molecular aggregates. When the solute drug eventually precipitates, relatively larger crystals are formed. [0011]
  • Lyophilization (freeze drying) has the advantage of allowing the solvent to be removed whilst keeping the solute relatively immobile, thereby suppressing enlargement of clusters or aggregates. When the solvent is removed, the formed crystals are smaller or the material is amorphous, reflecting the separation of the molecules in the frozen solution state. Molecular separation can be improved and aggregate formation still further suppressed by lyophilizing a more dilute solution, although one pays a hefty price in energy requirements for removing more solvent. Lyophilization is usually a very slow, energy intensive process and usually requires high vacuum equipment. Furthermore, there is a tendency for the crystals formed to aggregate in the free state, undoing the job that the freeze drying did. This tendency can sometimes be overcome with additives, but these must be compatible with the entire system. [0012]
  • Amorphous or nanoparticulate materials tend to show poor bulk flow properties as powders, requiring formulation work to be able to fill them into capsules. While these problems are not insurmountable, they add further limitations in the usefulness of the system. Many of the existing limitations are overcome by the present invention. [0013]
  • SUMMARY OF THE INVENTION
  • The present invention relates to a drug delivery vehicle including a pharmaceutical carrier particle, especially a pharmaceutical carrier particle that is a sugar particle, a starch particle, a lactose particle, or a particle of microcrystalline cellulose, bearing microparticles of a drug, especially a drug having poor solubility in water, wherein the microparticles of the drug are deposited on the pharmaceutical carrier particle from a solid solution of the drug in a sublimable carrier such as menthol, thymol, camphor, t-butanol, trichloro-t-butanol, imidazole, coumarin, acetic acid (glacial), dimethylsulfone, urea, vanillin, camphene, salicylamide, and 2-aminopyridine. The drug delivery vehicle of the present invention is useful for delivering a drug, especially a drug that has poor solubility in water, to a mammal, especially a human, in need of treatment with that drug. [0014]
  • In another aspect, the present invention relates to a method of making a microparticle including the steps of forming a solid solution of the drug in a sublimable carrier and removing the sublimable carrier from the solid solution by, for example, sublimation. Sublimation can be accomplished in a fluidized bed apparatus. [0015]
  • In another aspect, the present invention relates to a method of making a drug delivery vehicle including the steps of forming a solid solution of the drug and a sublimable carrier on the surface of a pharmaceutical carrier particle, especially a pharmaceutical carrier particle that is a sugar particle, a starch particle, a lactose particle, or a particle of microcrystalline cellulose, and removing the sublimable carrier from the solid solution, for example by sublimation, to deposit microparticles of the drug on the pharmaceutical carrier particle. The solid solution can be formed on the carrier particle by, for example, combining drug, sublimable carrier, and a solvent (for example ethanol), applying the combination to the carrier particle, and removing the solvent. The solid solution can also be formed by applying a combination of drug and molten sublimable carrier to the particle and allowing the combination to cool to form the solid solution on the carrier particle. [0016]
  • In yet another aspect, the present invention relates to pharmaceutical compositions that include microparticles of the present invention, which microparticles can be born by a drug delivery vehicle of the present invention. [0017]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides microparticles of a pharmacologically active substance, i.e. a drug, and a method for making them. The invention also provides a drug delivery vehicle for administering a pharmacologically active substance, and methods for making it, wherein the delivery vehicle includes at least one pharmaceutical carrier particle bearing microparticles of the drug, which microparticles are made according to the present invention. [0018]
  • Microparticles of the present invention are formed as described hereinbelow and generally have mean dimensions on the order of about 100 nm, up to about 10 μm. Microparticles according to the present invention can have a regular shape, e.g. essentially spherical, or they can have an irregular shape. The material of which microparticles are comprised can be crystalline or it can be at least partly amorphous. Preferably the material is at least partly amorphous. [0019]
  • As used herein in connection with a measured quantity, the term about refers to the normal variation in that measured quantity that would be expected by the skilled artisan making the measurement and exercising a level of care commensurate with the objective of the measurement and the precision of the measuring equipment used. [0020]
  • Any pharmagologically active substance (drug) can be used in the practice of the present invention. However, drugs having poor water solubility (poorly water soluble drugs), and hence relatively lower bioavailability, are preferred and the advantages of the present invention are more fully realized with poorly water-soluble drugs. For purposes of the present invention, a drug is considered to be poorly water soluble if it has a solubility of less than about 20 mg/per milliliter of water. Examples of drugs having poor water solubility include fenofibrate, itraconazole, bromocriptine, carbamazepine, diazepam, paclitaxel, etoposide, camptothecin, danazole, progesterone, nitrofurantoin, estradiol, estrone, oxfendazole, proquazone, ketoprofen, nifedipine, verapamil, and glyburide, to mention just a few. The skilled artisan knows other drugs having poor water solubility. [0021]
  • Pharmaceutical carrier particles useful for making the delivery vehicle of the present invention are made of comestible substances and are well known in the art. Examples of useful pharmaceutical carrier particles include particles, that can be non-pariel pellets, typically between about 0.1 mm. and about 2 mm. in diameter, and made of, for example, starch, particles of microcrystalline cellulose, lactose particles or, particularly, sugar particles. Suitable sugar particles (pellets, e.g. non-panel 103, Nu-core, Nu-pariel) are commercially available in sizes from 35 to 40 mesh to 18 to 14 mesh. Particles of microcrystalline cellulose are preferred pharmaceutical carrier particles. The skilled artisan knows other pellets or spheres useful as pharmaceutical carrier particles. [0022]
  • The microparticles of the drug or pharmacologically active substance of the present invention are obtained by removing a sublimable carrier from a solid solution of the drug in the sublimable carrier. The drug or pharamaceutically active substance can be present with the sublimable carrier in the solid solution as discrete molecules, or it can be present in aggregates of a few hundred, a few thousand, or more molecules. The drug need only be dispersed on a sufficiently small scale so that sufficiently small, discrete microparticles are ultimately obtained. Preferably, the drug or pharmagolocigally active substance in the solid solution is dissolved in the sublimable carrier. [0023]
  • Sublimable carriers useful in the practice of the present invention form solid solutions with the drug at an easily accessible temperature and can be removed from the solid solution without heating the solid solution to a temperature above the melting point of the solid solution, for example by sublimation. Sublimable carriers have a measurable vapor pressure below their melting point. Preferred sublimable carriers have a vapor pressure of at least about 10 Pascal, more preferably at least about 50 Pascal at about 10° or more below their normal melting points. Preferably, the sublimable carrier has a melting point between about −10° C. and about 200° C., more preferably between about 20° C. and about 60° C., most preferably between about 40° C. and about 50° C. Preferably, the sublimable carrier is a substance that is classified by the United States Food and Drug Administration as generally recognized as safe (i.e., GRAS). Examples of suitable sublimable carriers include menthol, thymol, camphor, t-butanol, trichloro-t-butanol, imidazole, coumarin, acetic acid (glacial), dimethylsulfone, urea, vanillin, camphene, salicylamide, and 2-aminopyridine. Menthol is a particularly preferred sublimable carrier. [0024]
  • The solid solutions of the present invention can exist as a true homogeneous crystalline phase of the interstitial or substitutional type, composed of distinct chemical species occupying the lattice points at random, or they can be a dispersion of discrete molecules or aggregates of molecules in the sublimable carrier. [0025]
  • The solid solutions can be made by combining a drug with molten sublimable carrier, then cooling the combination to below the melting point of the solid solution. The solid solutions can also be formed by combining drug and sublimable carrier in an organic solvent and evaporating the organic solvent to obtain a solid solution of drug in sublimable carrier. Ethanol is an example of a preferred organic solvent that can be used in the practice of the present invention. [0026]
  • The solid solution can also include a compound or polymer that forms a dispersion with the drug. [0027]
  • In a preferred embodiment, the solid solution is formed on the surface of at least one pharmaceutical carrier particle and preferably a plurality of pharmaceutical carrier particles. For example, a molten combination of drug and carrier can be applied to the surface of a pharmaceutical carrier particle where it is allowed to cool to form the solid solution on the surface of the pharmaceutical carrier particle. A solid solution can also be formed at the surface of a pharmaceutical carrier particle by applying a combination of solvent, drug, and sublimable carrier to at least one, and preferably a plurality of, pharmaceutical carrier particle(s) and evaporating the organic solvent to obtain the solid solution on the surface of the pharmaceutical carrier particle. [0028]
  • Application to the pharmaceutical carrier particles can be by any particle coating technique known in the art, for example using fluidized bed equipment or a spray coater. When used, organic solvent is removed after application by exposing the coated carrier particles to vacuum or a stream of heated or non-heated air using particle handling equipment well known in the art. [0029]
  • When no solvent is used, application is at a temperature above the melting point of the sublimable carrier. When drug and sublimable carrier are combined with solvent, application is at a temperature such that drug and sublimable carrier remain in solution in the solvent. [0030]
  • The microparticles of the present invention are formed by removal of sublimable carrier from a solid solution, made as described above, at a temperature below the melting point of the solid solution. The solid solution must be kept at a temperature below its melting point to preserve the solid solution during the process of removing the sublimable carrier. The sublimable carrier can be removed from the solid solution by, for example, treating the solid solution, deposited on a pharmaceutical carrier particle where applicable, in a stream of air, preferably heated air, in, for example, a fluidized bed drier. [0031]
  • In those embodiments in which the solid solution is coated on the surface of a pharmaceutical carrier particle, the sublimable carrier can be removed by exposing the coated particles to heat, vacuum, heat and vacuum, or to a stream of heated or non-heated air, for example in a fluidized bed dryer. Exposing coated pharmaceutical carrier particles to a stream of air (heated or not) in a fluidized bed dryer is a preferred means of removing sublimable carrier from solid solution coated on pharmaceutical carrier particles in order to form the microparticles of the present invention on the surface of the carrier particles. [0032]
  • Removal of sublimable carrier from the solid solution, whether coated on a pharmaceutical carrier particle or not, results in formation of the microparticles of the present invention. [0033]
  • In another embodiment of the present invention, the microparticles of drug or the pharmaceutical carrier particles bearing microparticles of a drug are formulated into pharmaceutical compositions that can be made into dosage forms, in particular oral solid dosage forms such as capsules and compressed tablets, as are well known in the art. [0034]
  • Compressed tablets are formulated from pharmaceutical compositions containing the microparticles of the pharmacologically active substance or drug, or using pharmaceutical carrier particles bearing such microparticles, and pharmacologically inert (pharmaceutically acceptable) additives or excipients. [0035]
  • For making a tablet, it will typically be desirable to include one or more benign pharmaceutical excipients in the pharmaceutical composition. The pharmaceutical composition of the present invention may contain one or more diluents added to make the tablet larger and, hence, easier for the patient and caregiver to handle. Common diluents are microcrystalline cellulose (e.g. Avicel®), microfine cellulose, lactose, starch, pregelitinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc. [0036]
  • Binders also may be included in tablet formulations to help hold the tablet together after compression. Some typical binders are acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate and starch. [0037]
  • The tablet may further include a disintegrant to accelerate disintegration of the tablet in the patient's stomach. Disintegrants include alginic acid, carboxymethyl cellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium (e.g. Ac-Di-Sol®, Primellose®), crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®) and starch. [0038]
  • A pharmaceutical composition for making compressed tablets may further include glidants, lubricants, flavorings, colorants and other commonly used excipients. [0039]
  • Pharmaceutical carrier particles bearing microparticles of a drug made in accordance with the present invention have excellent bulk flow properties and can be used directly, alone or in combination with carrier particles that do not carry a drug, to make capsule dosage forms. If necessary, diluents such as lactose, mannitol, calcium carbonate, and magnesium carbonate, to mention just a few, can be formulated with the microparticle-bearing pharmaceutical carrier particles when making capsules [0040]
  • Liquid oral pharmaceutical compositions of the present invention comprise microparticles or microparticle-bearing pharmaceutical carrier particles and a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin, most preferably water. [0041]
  • Liquid oral pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition the active ingredient, drug delivery vehicle, or excipient having low solubility in the liquid carrier. Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol. [0042]
  • Liquid oral pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum. [0043]
  • The liquid oral pharmaceutical composition also may contain sweetening agents, such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar; preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid; and buffers such as guconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate or sodium acetate.[0044]
  • The present invention is further illustarted with the followin non-limiting examples. [0045]
  • EXAMPLE 1 Solubility of Selected Drugs in Menthol
  • The following general procedure was repeated with several drugs with menthol carrier. [0046]
  • Menthol (10 grams) was melted on a stirring hot plate with magnetic stirring, then heated to the desired temperature indicated in Table 1. The desired drug was added in small increments (0.1 grams) and stirred to obtain a clear solution. The desired drug was added in increments until no more drug dissolved in the menthol. The weight of material added to the menthol melt that still gave a clear solution was taken as the solubility of the active drug at the indicated temperature. The results are given in Table 1. [0047]
    TABLE 1
    Solubility of selected active drug substances in menthol
    Active drug Solubility
    substance temperature (° C.) (% w/w)
    Azithromycin 63 40.0
    Cyclosporin 55 39.2
    Diazepam 43 5.7
    Fenofibrate 60 37.5
    Itraconazole 61 1.0
    Oxybutynin 60 9.1
    Risperidone 70 8.3
    Salicylic acid 43 16.0
    Simvastatin 63 30.0
  • EXAMPLE 2 Improvement of the Dissolution of Fenofibrate by “Menthol Micronization”
  • Menthol (50 grams) was heated in a jacketed reactor to 60° C. After melting, the melt was stirred at 100 rpm. Fenofibrate (25 grams) was added and the mixture stirred at 100 rpm and 60° C. until full dissolution was achieved. Microcrystalline cellulose (Avicel ph 102, 55 grams) was added to the melt and the mixture was stirred for 30 minutes. The heat source was then removed and the mass allowed to cool to room temperature with the stirring continued at 100 rpm for a further 30 minutes. [0048]
  • The obtained mass was milled through a 6.35 mm screen in a Quadro Comil mill at 1300 rpm. The milled product was allowed to cool to 25° C. and milled again through 1.4 mm screen to obtain a powder in which the fenofibrate is dissolved in menthol and coated on the microcrystalline cellulose. [0049]
  • The powder was transferred to a fluid bed dryer (Aeromatic model STREA1) where the menthol was removed by drying for three hours at 30-32° C. with the fan at 7-8 Nm[0050] 3/hr. A powder, 62 grams, was obtained. This powder was an essentially “micronized” fenofibrate deposited on microcrystalline cellulose.
  • A sample of this powder containing 100 mg of the fenofibrate was tested for dissolution in a USP Apparatus II dissolution tester in 900 ml 0.5% sodium lauryl sulfate (SLS) in water at 37° C. and 100 rpm. The fenofibrate in the dissolution medium was determined by HPLC on an Hypersil® ODS column with UV detection at 286 nm. The results are shown in Table 2. Fenofibrate “micronized” by the menthol method gave 100% dissolution in two hours. An equivalent simple combination of fenofibrate (control, not deposited from menthol) with microcrystalline cellulose gave 40.2% dissolution in 3 hours, while a mechanically micronized fenofibrate raw material mixed with microcrystalline cellulose gave 72.1% dissolution in 3 hours. [0051]
    TABLE 2
    Dissolution of menthol treated fenofibrate
    time (minutes) % dissolved
    15 44.0 +/− 1.3
    30 73.6 +/− 2.9
    60 82.3 +/− 0.6
    90 93.1 +/− 4.2
    120 102.7 +/− 0.2 
    180 104.9 +/− 0.8 
  • EXAMPLE 3 Improvement of the Dissolution of Oxybutynin Chloride by “Menthol Micronization”
  • Menthol (80 grams) was melted and oxybutynin chloride (8 grams) and microcrystalline cellulose (89.5 grams) were added and treated as in Example 2 to give a powder of “micronized” oxybutynin chloride on microcrystalline cellulose. [0052]
  • The dissolution of oxybutynin chloride from this powder (a sample of powder containing 100 mg of the active drug) was tested in a USP apparatus II dissolution tester in 100 ml of 50 mM phosphate buffer pH=6.8 at 37° C. and 50 rpm. The oxybutynin content of the dissolution sample was measured by spectrophotometer at 225 nm. The results are given in Table 3. The dissolution reached 79.2% at three hours. An equivalent simple combination of the oxybutynin chloride raw material with microcrystalline cellulose that was not treated with the “menthol micronization” method gave only 22.1% dissolution in three hours. [0053]
    TABLE 3
    Dissolution of menthol treated oxybutynin
    time (minutes) % dissolved
    30 21.5 +/− 0.4
    90 59.7 +/− 1.2
    180 79.2 +/− 1.0
  • EXAMPLE 4 Improvement of the Dissolution of Risperidone by “Menthol Micronization”
  • Menthol (50 grams) was melted and risperidone (4.5 grams) and microcrystalline cellulose (62.5 grams) were added and treated according to the procedure in Example 2. A sample of the resulting powder (containing 50 mg of risperidone) was tested in a USP apparatus II dissolution tester using 900 ml of water at 37° C. and 100 rpm. The concentration of risperidone in the dissolution samples was measured using a spectrophotometer at 240 nm. [0054]
  • The results of the dissolution of the “menthol micronized” powder and of the control simple combination of risperidone and microcrystalline cellulose (not treated with menthol) are shown in Table 4. The menthol deposited risperidone gave 100% dissolution in 30 minutes, whereas the control mixture gave 31.9% in thirty minutes and 63.7% in three hours. [0055]
    TABLE 4
    Dissolution of menthol treated risperidone vs. control
    time (minutes) % dissolved test % dissolved control
    15 69.3 +/− 0.5 17.5 +/− 2.6
    30 99.9 +/− 1.0 31.9 +/− 3.5
    60 102.3 +/− 0.8  41.7 +/− 5.6
    90 102.8 +/− 1.2  48.2 +/− 8.3
    120  53.2 +/− 11.1
    180 63.7 +/− 8.3
  • EXAMPLE 5 Improvement of the Dissolution of Cyclosporin by “Menthol Micronization”
  • Menthol (80 grams) was melted and cyclosporin (20 grams) and microcrystalline cellulose (100 grams) were added and treated as in Example 2. A sample of this powder (containing 10 mg of “menthol micronized” cyclosporin) was tested for dissolution in 900 ml water in a USP apparatus II dissolution unit at 37° C. and 100 rpm. The cyclosporin content of the dissolution samples was determined spectrophotometrically at 215 nm. The dissolution of the menthol deposited material and of a control mixture of cyclosporin and microcrystalline cellulose (not deposited from menthol) are presented in Table 5. The cyclosporin dissolution from the powder having cyclosporin deposited from menthol was about twice that of the control (simple combination), and the maximum dissolution was achieved in shorter time. [0056]
    TABLE 5
    Dissolution of menthol treated cyclosporin vs. control
    time (minutes) % dissolved test % dissolved control
    30  9.2 +/− 0.3 0.1 +/− 0.0
    60 11.9 +/− 0.3 1.3 +/− 0.5
    90 13.1 +/− 0.5 3.1 +/− 0.2
    120 13.3 +/− 0.3 5.1 +/− 0.2
    180 14.3 +/− 0.8 7.1 +/− 0.3
  • EXAMPLE 6 (COMPARATIVE) Attempted Improvement in Itraconazole Dissolution by “Menthol Micronization”
  • Menthol (92 grams) was melted as in Example 2. Itraconazole (3.6 grams) was added and mixed well in the melt. A solution was not formed because itraconazole has a solubility of only 1% in menthol at 60° C. (see Table 1). To the suspension of itraconazole in menthol was added microcrystalline cellulose (90 grams) and the mixture treated as in Example 2. The dissolution of the itraconazole was measured from a powder sample containing 100 mg of the drug in 900 ml of 0.1N HCl in a USP apparatus II dissolution tester at 37° C. and 100 rpm. The dissolved itraconazole was measured spectrophotometrically at 251 nm. The results of the dissolution are shown in Table 6. The dissolution was about 8% at 30 minutes and the same at three hours. A control simple mixture of itraconazole and microcrystalline cellulose (not deposited from menthol) gave essentially the same results (7.8% in three hours). [0057]
    TABLE 6
    Dissolution of menthol treated itraconazole
    time (minutes) % dissolved
    30 8.8 +/− 0.4
    90 8.0 +/− 0.6
    180 8.1 +/− 0.1
  • REFERENCES
  • (1) Nielsen, L. S. Improved peroral bioavailability of mebendazole in rabbits by administration of various N-alkoxycarbonyl derivatives of mebendazole, [0058] Int. J. Pharm. 104, 175-179 (1994)
  • (2) Chan, O. H. et. al. Evaluation of a targeted prodrug strategy to enhance oral absorption of poorly water soluble compounds, [0059] Pharm. Res. 15, 1012-1018 (1998)
  • (3) Fleisher, D. et. al. Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs, [0060] Adv. Drug Deliv. Rev. 19, 115-130 (1996)
  • (4) Abang, A. M. The clinical pharmacology of topoisomerase I inhibitors, [0061] Semin. Hematol. 35 Suppl 4, 13-21 (1998)
  • (5) Merisko-Liversidge, E., Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, [0062] Pharm. Res. 13, 272-278 (1996);
  • (6) Liversidge, G. G., Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs, [0063] Int. J. Pharm., 125, 91-97 (1995)
  • (7) Muller, R. H., et. al. Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size reduction technique, [0064] Int. J. Pharm. 160, 229-237 (1998)
  • (8) Muller, R. H. et. al. , Increase of solubility of poorly soluble drugs by transfer to DissoCubes™ using high pressure homogenization, [0065] Proc. Control. Release Soc. 1999, 112-113,
  • (9) U.S. Pat. No. 6,346,533 to Cha et. al [0066]
  • (10) Morita, T. et. al. Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixtures, [0067] Pharm. Res. 17, 1367-1373 (2000)
  • (11) Tesconi, M. S., Freeze drying above room temperature, [0068] J. Pharm. Sci. 88, 501-506 (1999)
  • (12) Ni, N. et. al. Use of pure butanol as a solvent for freeze drying: a case study, [0069] Int. J. Pharm. 226, 39-46 (2001)
  • (13a) U.S. Pat. No. 3,089,818 assigned to Baxter laboratories [0070]
  • (13) U.S. Pat. No. 4,900,775 to Smith et. al [0071]
  • (14) Wenz, G. An overview of host-guest chemistry and its application to nonsteroidal anti-inflammatory drugs, [0072] Clin. Drug Invest. 19 (suppl 2), 21-25 (2000)
  • (15) Cappello, B., Solubilization of tropicamide by hydroxypropyl-β-cyclodextrin and water soluble polymers: In vitro/in vivo studies, [0073] Int. J. Pharm. 213, 75-81 (2001)
  • (16) Sekiguchi et. al. [0074] Chem Pharm. Bull. 9, 866-872 (1961)
  • (17) Chiou et. al. [0075] J. Pharm. Sci. 60, 1281-1302 (1971)
  • (18) Fernandez, M. et. al., Characterization of solid dispersions of piroxicam/polyethylene glycol 4000, [0076] Int. J. Pharm. 84, 197-202 (1992)
  • (19) Margarit, M. V. et. al. , Physical characteristics and dissolution kinetics of solid dispersions of ketoprofen and polyethylene glycol 6000, [0077] Int. J. Pharm. 108, 101-108 (1994)
  • (20) Sheen, P. C. et. al., Formulation of poorly water-soluble drug in solid dispersions to improve bioavailability, [0078] Int. J. Pharm. 118, 221-227 (1995)
  • (21) Kai, T. et. al., Oral absorption of poorly soluble drug using solid dispersion technique, [0079] Chem. Pharm. Bull. 44, 568-571 (1996)
  • (22) Serajuddin, A. T. M., Solid dispersions of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs, [0080] J. Pharm. Sci., 88, 1058-1066 (1999)
  • (23) Lee, E. J. et. al. , Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres, [0081] Int. J. Pharm., 218,125-131(2001)
  • (24) Kapsi, S. G. et. al. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability, [0082] Int. J. Pharm., 229, 193-203 (2001)
  • (25) Ho, H. O., The preparation and characterization of solid dispersions on pellets using a fluidized bed system, [0083] Int. J. Pharm. 139, 223-239 (1996)
  • (26) U.S. Pat. No. 6,027,747 to Terracol et. al. [0084]
  • (27) Betageri, G. V. et. al. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques, [0085] Int. J. Pharm. 126, 155-160 (1995)
  • (28) Gupta, M. K. et. al. Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent, [0086] Pharm. Dev. Technol. 6, 563-572 (2001)

Claims (20)

    What is claimed is;
  1. 1. A drug delivery vehicle comprising a pharmaceutical carrier particle bearing microparticles of a drug deposited on the pharmaceutical carrier particle from a solid solution of the drug in a sublimable carrier.
  2. 2. The drug delivery vehicle of claim 1 wherein the drug is a poorly water soluble drug.
  3. 3. The drug delivery vehicle of claim 2 wherein the poorly water soluble drug is selected from the group consisting of: fenofibrate, itraconazole, bromocriptine, carbamazepine, diazepam, paclitaxel, etoposide, camptothecin, danazole, progesterone, nitrofurantoin, estradiol, estrone, oxfendazole, proquazone, ketoprofen, nifedipine, verapamil, and glyburide.
  4. 4. The drug delivery vehicle of claim 1 wherein the sublimable carrier comprises one or more members selected from the group consisting of menthol, thymol, camphor, t-butanol, trichloro-t-butanol, imidazole, coumarin, acetic acid (glacial), dimethylsulfone, urea, vanillin, camphene, salicylamide, and 2-aminopyridine.
  5. 5. The drug delivery vehicle of claim 4 wherein the sublimable carrier is menthol.
  6. 6. The drug delivery vehicle of claim 1 wherein the pharmaceuticle carrier particle comprises at least on pharmaceutical particle selected from starch particles, microcrystalline starch particles, microcrystalline cellulose particles, lactose particles, and sugar particles.
  7. 7. The drug delivery vehilcle of claim 6 wherein the pharmaceutical carrier particle comprises particles of microcrystalline cellulose.
  8. 8. The method of claim 6 wherein the solid solution is formed by combining the drug and sublimable carrier with an organic solvent and thereafter evaporating the organic solvent to obtain the solid solution.
  9. 9. A method of making a drug delivery vehicle comprising the steps of:
    a) forming a solid solution of the drug and a sublimable carrier on the surface of a pharmaceutical carrier particle, and
    b) subliming the sublimable carrier from the solid solution to deposit microparticles of the drug on the surface of the pharmaceutical carrier particle to obtain the drug delivery vehicle.
  10. 10. The method of claim 9 wherein the solid solution is formed by combining the drug with molten sublimable carrier, applying the combination to at least one pharmaceutical carrier particle, and thereafter allowing the combination to solidify to obtain the solid solution on the surface of the pharmaceutical carrier particle.
  11. 11. The method of claim 9 wherein the solid solution is formed by combining the drug and the sublimable carrier with an organic solvent, applying the combination to at least one pharmaceutical carrier particle, and evaporating the organic solvent to obtain the solid solution on the surface of the at least one pharmaceutical carrier particle.
  12. 12. The method of claim 11 wherein the solvent is ethanol.
  13. 13. The method of claim 9 wherein the drug is selected from the group consisting of fenofibrate, itraconazole, bromocriptine, carbamazepine, diazepam, paclitaxel, etoposide, camptothecin, danazole, progesterone, nitrofurantoin, estradiol, estrone, oxfendazole, proquazone, ketoprofen, nifedipine, verapamil, and glyburide.
  14. 14. The method of claim 9 wherein the sublimable carrier is selected from the group consisting of menthol, thymol, camphor, t-butanol, trichloro-t-butanol, imidazole, coumarin, acetic acid (glacial), dimethylsulfone, urea, vanillin, camphene, salicylamide, and 2-aminopyridine.
  15. 15. The method of claim 9 wherein the pharmaceutical carrier particle is selected from the group consisting of starch particles, sugar particles, lactose particles, particles of microcrystalline cellulose, and mixtures of any of these.
  16. 16. The method of claim 9 wherein the sublimable carrier is sublimed from the solid solution by treating the pharmaceitical carrier particles in a fludized bed drier at a temperature below the melting point of the solid solution.
  17. 17. A pharmaceutical composition comprising a plurality of microparticles of a drug and at least one pharmaceutically acceptable excipient, wherein the microparticles are formed by removing sublimable carrier from a solid solution of the drug in the sublimable carrier.
  18. 18. The pharmaceutical composition of claim 17 wherein the solid solution is formed on the surface of a plurality of pharmaceutical carrier particle.
  19. 19. The pharmaceutical composition of claim 17 wherein the sublimable carrier is removed from the solid solution that is on the surfaces of the plurality of pharmaceutical carrier particles, whereby the plurality of microparticles are born by the plurality of pharmaceutical carrier particles.
  20. 20. An oral solid dosage form comprising a pharmaceutical composition according to claim 16.
US10400100 2002-03-26 2003-03-25 Drug microparticles Abandoned US20030224059A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US36795702 true 2002-03-26 2002-03-26
US10400100 US20030224059A1 (en) 2002-03-26 2003-03-25 Drug microparticles

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10400100 US20030224059A1 (en) 2002-03-26 2003-03-25 Drug microparticles
US11357248 US20060141051A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11357757 US20060141052A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11356682 US20060141050A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US12635417 US8663703B2 (en) 2002-03-26 2009-12-10 Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them
US14156714 US9107832B2 (en) 2002-03-26 2014-01-16 Risperidone microparticles formed by sublimation

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11357248 Continuation US20060141051A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11357757 Continuation US20060141052A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11356682 Continuation US20060141050A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US12635417 Division US8663703B2 (en) 2002-03-26 2009-12-10 Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them

Publications (1)

Publication Number Publication Date
US20030224059A1 true true US20030224059A1 (en) 2003-12-04

Family

ID=28675427

Family Applications (6)

Application Number Title Priority Date Filing Date
US10400100 Abandoned US20030224059A1 (en) 2002-03-26 2003-03-25 Drug microparticles
US11357248 Abandoned US20060141051A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11357757 Abandoned US20060141052A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11356682 Abandoned US20060141050A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US12635417 Active 2024-03-16 US8663703B2 (en) 2002-03-26 2009-12-10 Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them
US14156714 Active US9107832B2 (en) 2002-03-26 2014-01-16 Risperidone microparticles formed by sublimation

Family Applications After (5)

Application Number Title Priority Date Filing Date
US11357248 Abandoned US20060141051A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11357757 Abandoned US20060141052A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US11356682 Abandoned US20060141050A1 (en) 2002-03-26 2006-02-17 Drug microparticles
US12635417 Active 2024-03-16 US8663703B2 (en) 2002-03-26 2009-12-10 Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them
US14156714 Active US9107832B2 (en) 2002-03-26 2014-01-16 Risperidone microparticles formed by sublimation

Country Status (9)

Country Link
US (6) US20030224059A1 (en)
EP (5) EP2085073A1 (en)
JP (1) JP2005531521A (en)
KR (1) KR20040098023A (en)
CA (1) CA2480377A1 (en)
DE (1) DE60330322D1 (en)
DK (1) DK1487416T3 (en)
ES (1) ES2334991T3 (en)
WO (1) WO2003082247A3 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
EP1707196A1 (en) * 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20060222707A1 (en) * 2005-03-30 2006-10-05 Lerner E I Formulations of fenofibrate
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
EP1803441A1 (en) 2005-12-28 2007-07-04 Teva Pharmaceutical Industries Ltd Pharmaceutical formulations of fenofibrate having improved bioavailability
WO2007075171A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
KR100790954B1 (en) * 2007-09-13 2008-01-04 영남대학교 산학협력단 Novel composite of gelatin ultra-micro capsule containing itraconazole
US20100151035A1 (en) * 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
WO2010137888A2 (en) 2009-05-27 2010-12-02 주식회사 삼양사 Microspheres with improved bioavailability containing poorly water-soluble drugs, and method for preparing same
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1487416T3 (en) 2002-03-26 2010-03-29 Teva Pharma Drug Microparticles
JP2006524190A (en) * 2003-02-20 2006-10-26 テバ ファーマシューティカル インダストリーズ リミティド Menthol solution of the drug
WO2005053660A3 (en) * 2003-12-03 2005-10-20 Lifecycle Pharma As Pharmaceutical compositions comprising danazol
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20060141028A1 (en) * 2004-08-13 2006-06-29 Moshe Flashner-Barak Cyclosporin formulations
EP1954298A4 (en) 2005-11-28 2012-10-31 Imaginot Pty Ltd Oral therapeutic compound delivery system
CA2647073A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Drug microparticles
JP5793076B2 (en) 2008-05-28 2015-10-14 プロセラ バイオロジクス, インコーポレイテッド Blood-derived inter - alpha - Preparation and composition of the inhibitor protein.
CA2750711C (en) 2009-01-26 2015-07-07 Teva Pharmaceutical Industries Ltd. Processes for coating a carrier with microparticles
WO2013003619A1 (en) 2011-06-29 2013-01-03 Tyco Healthcare Group Lp Dissolution of oxidized cellulose
WO2013163453A1 (en) * 2012-04-25 2013-10-31 Spi Pharma, Inc. Crystalline microspheres and the process for manufacturing the same
US9271937B2 (en) 2012-05-31 2016-03-01 Covidien Lp Oxidized cellulose microspheres
US20180056261A1 (en) * 2016-08-30 2018-03-01 Allergan, Inc. Method of manufacturing coated beads

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US4900775A (en) * 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5460828A (en) * 1993-01-28 1995-10-24 Recordati S.A., Chemical And Pharmaceutical Company Process for the preparation of microgranules suitable for suspension in fluids
US5529789A (en) * 1992-03-17 1996-06-25 Pfizer, Inc. Method of producing porous delivery devices
US5985248A (en) * 1996-12-31 1999-11-16 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs and compositions thereof
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6074670A (en) * 1997-01-17 2000-06-13 Laboratoires Fournier, S.A. Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6346533B1 (en) * 1997-06-16 2002-02-12 Dong-A Pharmaceutical Co., Ltd. Intraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
US20030138496A1 (en) * 2000-08-09 2003-07-24 Ching-Ling Teng Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US20040058009A1 (en) * 2002-05-24 2004-03-25 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6761910B1 (en) * 1998-09-24 2004-07-13 Diabact Ab Pharmaceutical composition for the treatment of acute disorders
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (en) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh A process for the production of porous tablets
JPS5429566B2 (en) 1974-09-13 1979-09-25
GB8921710D0 (en) * 1989-09-26 1989-11-08 Mentholatum Co Ltd Ibuprofen triturates and topical compositions containing same
DK0669128T3 (en) * 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical The sustained-release microsphere containing antipsychotic and process for producing same
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
DK1313564T3 (en) * 2000-04-26 2010-04-06 Elan Pharma Int Ltd Apparatus for hygienically wet milling
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
KR20010107754A (en) * 2000-05-26 2001-12-07 민경윤 Process for preparing rapidly disintegrating tablet for oral administration
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
DK1487416T3 (en) 2002-03-26 2010-03-29 Teva Pharma Drug Microparticles
US20020193386A1 (en) * 2002-03-28 2002-12-19 Inigo Pfeiffer Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004075874A1 (en) 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
US20040185108A1 (en) * 2003-03-18 2004-09-23 Short Robert E. Method of preparing gas-filled polymer matrix microparticles useful for delivering drug
EP1680086A2 (en) 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US4900775A (en) * 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5529789A (en) * 1992-03-17 1996-06-25 Pfizer, Inc. Method of producing porous delivery devices
US5460828A (en) * 1993-01-28 1995-10-24 Recordati S.A., Chemical And Pharmaceutical Company Process for the preparation of microgranules suitable for suspension in fluids
US5985248A (en) * 1996-12-31 1999-11-16 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs and compositions thereof
US6074670A (en) * 1997-01-17 2000-06-13 Laboratoires Fournier, S.A. Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6346533B1 (en) * 1997-06-16 2002-02-12 Dong-A Pharmaceutical Co., Ltd. Intraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6761910B1 (en) * 1998-09-24 2004-07-13 Diabact Ab Pharmaceutical composition for the treatment of acute disorders
US20030138496A1 (en) * 2000-08-09 2003-07-24 Ching-Ling Teng Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7081450B2 (en) * 2001-09-28 2006-07-25 Solubest Ltd. Water soluble nanoparticles of hydrophilic and hydrophobic active materials and an apparatus and method for their production
US20040058009A1 (en) * 2002-05-24 2004-03-25 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20050276974A1 (en) * 2002-05-24 2005-12-15 Elan Pharma Internationl, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7320802B2 (en) * 2002-05-24 2008-01-22 Elan Pharma International, Ltd. Methods of treatment using nanoparticulate fenofibrate compositions

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
JP2008505934A (en) * 2005-03-30 2008-02-28 テバ ファーマシューティカル インダストリーズ リミティド Improved formulation of fenofibrate containing menthol or peg / poloxamer
EP1707196A1 (en) * 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate
US20060222707A1 (en) * 2005-03-30 2006-10-05 Lerner E I Formulations of fenofibrate
US20060222706A1 (en) * 2005-03-30 2006-10-05 Moshe Flashner-Barak Formulations of Fenofibrate
WO2006107316A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
WO2006107411A2 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and surfacant mixture
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
WO2006107411A3 (en) * 2005-03-30 2007-03-08 Teva Pharma Formulations containing fenofibrate and surfacant mixture
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
EP1803441A1 (en) 2005-12-28 2007-07-04 Teva Pharmaceutical Industries Ltd Pharmaceutical formulations of fenofibrate having improved bioavailability
WO2007075171A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
US20100151035A1 (en) * 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
KR100790954B1 (en) * 2007-09-13 2008-01-04 영남대학교 산학협력단 Novel composite of gelatin ultra-micro capsule containing itraconazole
US9511026B2 (en) 2009-05-27 2016-12-06 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microspheres with improved bioavailability and method of preparing the same
WO2010137888A2 (en) 2009-05-27 2010-12-02 주식회사 삼양사 Microspheres with improved bioavailability containing poorly water-soluble drugs, and method for preparing same
US8846649B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846648B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Also Published As

Publication number Publication date Type
EP2085073A1 (en) 2009-08-05 application
KR20040098023A (en) 2004-11-18 application
JP2005531521A (en) 2005-10-20 application
WO2003082247A2 (en) 2003-10-09 application
US20100092568A1 (en) 2010-04-15 application
EP1487416B1 (en) 2009-12-02 grant
US20060141052A1 (en) 2006-06-29 application
DE60330322D1 (en) 2010-01-14 grant
EP1487416A2 (en) 2004-12-22 application
WO2003082247A3 (en) 2004-02-05 application
EP2087882A1 (en) 2009-08-12 application
ES2334991T3 (en) 2010-03-18 grant
CA2480377A1 (en) 2003-10-09 application
US20140134256A1 (en) 2014-05-15 application
US20060141050A1 (en) 2006-06-29 application
US8663703B2 (en) 2014-03-04 grant
US20060141051A1 (en) 2006-06-29 application
DK1487416T3 (en) 2010-03-29 grant
EP2085074A1 (en) 2009-08-05 application
US9107832B2 (en) 2015-08-18 grant
EP2085072A1 (en) 2009-08-05 application

Similar Documents

Publication Publication Date Title
US6368620B2 (en) Formulations comprising lipid-regulating agents
US5718919A (en) Nanoparticles containing the R(-)enantiomer of ibuprofen
US6337092B1 (en) Composition and method of preparing microparticles of water-insoluble substances
US5776495A (en) Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US20020009494A1 (en) Solid pharmaceutical dispersions with enhanced bioavailability
US6027747A (en) Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6800297B2 (en) Porous COX-2 inhibitor matrices and methods of manufacture thereof
US6682761B2 (en) Water-insoluble drug particle process
US6375986B1 (en) Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US5846971A (en) Oral antifungal composition
US7101574B1 (en) Pharmaceutical composition containing fenofibrate and the preparation method
US6068858A (en) Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US7320802B2 (en) Methods of treatment using nanoparticulate fenofibrate compositions
US5591456A (en) Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US6221400B1 (en) Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
US20030194442A1 (en) Insoluble drug particle compositions with improved fasted-fed effects
US7833550B2 (en) Dry powder formulations of antihistamine for nasal administration
Liu et al. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles
US20030224058A1 (en) Nanoparticulate fibrate formulations
US6730319B2 (en) Pharmaceutical compositions having depressed melting points
US20010048946A1 (en) Solid pharmaceutical dosage forms in form of a particulate dispersion
WO2002024169A1 (en) Spray drying process and compositions of fenofibrate
US20040091535A1 (en) Coated tablets
Basa et al. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles
Rasenack et al. Preparation of microcrystals by in situ micronization

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF RIGHTS IN BARBADOS;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:014316/0079

Effective date: 20030616

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LERNER, E. ITZHAK;ROSENBERGER, VERED;FLASHNER-BARAK, MOSHE;AND OTHERS;REEL/FRAME:014316/0069;SIGNING DATES FROM 20030527 TO 20030625